Navigation Links
First of its kind study identifies risk factors for LRTIs in Inuit children
Date:5/21/2009

TORONTO, Ont. May 21, 2009 Inuit children have the highest rate of hospital admission for Lower respiratory tract infections (LRTIs) globally, but new research shows that lowering risk factors though public health interventions and an enhanced immunization program could improve health for Inuit children and lower health care costs significantly. The first-of-its-kind case control research was conducted by Dr. Anna Banerji, a pediatric infectious disease specialist and researcher at St. Michael's Hospital.

"Infants of Inuit race were nearly four times more likely to be admitted for LRTI than mixed or non-Inuit infants," explains Dr. Banerji. "LRTI increases the risk of recurrent infections, chronic lung disease and asthma so there are many potential health complications." According to recent Statistics Canada data, the Aboriginal infant mortality rate in Nunavut is two-to-three times the Canadian average so exploring the effectiveness of immunization could have a major impact on children's health and mortality rates.

Respiratory infections are the leading cause for admission, medical evacuation and expenditure for Inuit children in the health care system and can result in serious health complications for those affected. Dr. Banerji's key findings on the risk factors that contribute to LRTIs among Inuit children include:

  • Infants of mothers who smoked during pregnancy were four times more likely to be admitted for LRTI
  • Inuit infants were four times more likely to be admitted for LRTI than mixed or non-Inuit infants. It was not determined if this was a result of genetic factors or socio-economic factors
  • Overcrowded living conditions increased the risk of admission by 2.5 times
  • Living in a rural community without a hospital increased risk of admission by 2.7 times
  • Prematurity was not associated with an increased risk of admission
  • Infants who were not breast-fed were 3.6 times more likely to be admitted for LRTI
  • Infants who were custom adopted had 4.4 times the risk

Dr. Banerji also conducted a cost analysis by age and location that compared the costs of administering Palivisumab prophylaxis vaccine, an antibody approved for the prevention of respiratory syncytial virus (RSV) the most common cause of lower respiratory tract infections. The vaccine is used only for prevention and is usually a monthly injection during RSV season.

The results demonstrated that by immunizing rural Inuit infants with the vaccine, the health care system could save money up to $8,000 per admission avoided. The analysis concludes that preventative measures in infancy can both improve the health of children and result in a significant cost savings for the health-care system.

Dr. Banerji's research papers are posted online as of today (Thursday, May 21) in the Published Ahead-Of-Print section of The Pediatric Infectious Disease Journal website (www.journals.lww.com/pidj).

The research by Dr. Banerji is the second major study on Indigenous children's health recently released by the Keenan Research Centre at Li Ka Shing Knowledge Institute of St. Michael's Hospital. Earlier this year, the centre released the Indigenous Children's Health Report: Health Assessment in Action a project led by Dr. Janet Smylie.


'/>"/>

Contact: Tina Quelch
tina@calador.ca
416-925-6034
St. Michael's Hospital
Source:Eurekalert

Related medicine news :

1. MedPro Imaging Reports 118 Percent Growth For First Quarter
2. Cord Blood America, Inc. Announces 2009 First Quarter Results
3. Watson Launches GELNIQUE(TM) (oxybutynin chloride) Gel 10%, First and Only Topical Gel for Overactive Bladder (OAB)
4. Hummingbird Coaching Partners with Leeza's Place to Help Caregivers “Take Your Oxygen First”
5. Leading US Pediatric Hospital Draws First Dose with RIVA System
6. TrinityCare Senior Living, Inc. Announces First Quarter Operating Results
7. Parata Earns Pharmacy Industrys First-Ever GREENGUARD Certification for Indoor Air Quality
8. Encorium Reports First Quarter 2009 Financial Results
9. 3SBio Inc. Announces Unaudited First Quarter 2009 Results
10. International Isotopes Inc. Announces First Quarter 2009 Financial Results
11. Cylene to Announce New Data on Its First-in-Class Oral CK2 Inhibitor Against Cancer at BIO Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2016)... NY (PRWEB) , ... December 03, 2016 , ... ... non-profit organization devoted exclusively to funding innovative lymphoma research and serving the lymphoma ... – hosted its first Swirl: A Wine Tasting Event in New York City, ...
(Date:12/4/2016)... ... December 03, 2016 , ... Houston ... the 2016 Anti-Aging & Beauty Awards at The Aesthetic & Anti-aging Medicine ... Medicine European Congress (AMEC) brings together the industry’s leading scientific experts, speakers, ...
(Date:12/4/2016)... (PRWEB) , ... December 04, 2016 , ... ... undergoing major cosmetic surgery can now take advantage of a cosmetic procedure known ... skin rejuvenation treatment that reduces the appearance of age spots, fine lines, ...
(Date:12/2/2016)... ... December 02, 2016 , ... Halfway through its partnership with ... preventative dental services to more than 15,900 children 5 years old and younger and ... $38 million over a span of five years to Western University of Health Sciences, ...
(Date:12/2/2016)... ... 02, 2016 , ... On Dec. 2, 2016, CURE® magazine will host the ... the 2016 MPN Heroes—eight individuals who have made a difference in the field of ... standard of care, demonstrating leadership within the MPN community and/or a commitment to individual ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... TAIPEI, Taiwan , Dec. 5, 2016 /PRNewswire/ ... ropeginterferon alfa-2b showed non-inferiority to hydroxyurea (HU) in Complete Hematologic ... safety and tolerability profile of ropeginterferon alfa-2b versus HU ... the ongoing long-term follow-up trial CONTINUATION-PV to obtain European marketing ... to present this data to the FDA as it seeks ...
(Date:12/4/2016)... -- Sickle cell disease (SCD) is an inherited chronic ... get stuck in veins and block blood flow, which ... leading to death. Each year, approximately 300,000 people around ... them lack access to comprehensive care or effective treatment ... SCD, a pill called hydroxyurea approved more than a ...
(Date:12/2/2016)... SILVER SPRING, Md. , Dec. 2, 2016 /PRNewswire-USNewswire/ ... a new indication for Jardiance (empagliflozin) to reduce the ... 2 diabetes mellitus and cardiovascular disease. ... adults with type 2 diabetes mellitus," said Jean-Marc ... Metabolism and Endocrinology Products in FDA,s Center for Drug ...
Breaking Medicine Technology: